Dirk-Thomas Waldschmidt
Overview
Explore the profile of Dirk-Thomas Waldschmidt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
812
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gairing S, Mildenberger P, Gile J, Artusa F, Scheiner B, Leyh C, et al.
JHEP Rep
. 2025 Mar;
7(3):101295.
PMID: 40059970
Background & Aims: Immunotherapy with atezolizumab and bevacizumab (a + b) has improved the prognosis of patients with unresectable hepatocellular carcinoma (HCC). However, the outcome for individual patients is highly...
2.
Mitzlaff K, Kirstein M, Muller C, Venerito M, Olkus A, Dill M, et al.
United European Gastroenterol J
. 2024 Sep;
12(9):1230-1242.
PMID: 39301763
Background: Combined Immuno-chemotherapy consisting of gemcitabine, cisplatin and the programmed death-ligand one inhibitor durvalumab (GCD) is the new standard of care for patients with biliary tract cancers (BTC) based on...
3.
Reutter T, Fassunke J, Pusken M, Weber J, Binot E, Eisert A, et al.
JCO Precis Oncol
. 2023 Apr;
7:e2200467.
PMID: 37079858
No abstract available.
4.
Scheiner B, Pomej K, Kirstein M, Hucke F, Finkelmeier F, Waidmann O, et al.
J Hepatol
. 2021 Oct;
76(2):353-363.
PMID: 34648895
Background & Aims: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival...
5.
Finkelmeier F, Scheiner B, Leyh C, Best J, Frundt T, Czauderna C, et al.
Liver Cancer
. 2021 Aug;
10(4):360-369.
PMID: 34414123
Background And Aims: The multikinase inhibitor cabozantinib has been approved for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report safety and efficacy data of an international, multicenter, real-life cohort...
6.
Javle M, Roychowdhury S, Kelley R, Sadeghi S, Macarulla T, Weiss K, et al.
Lancet Gastroenterol Hepatol
. 2021 Aug;
6(10):803-815.
PMID: 34358484
Background: Treatment options are sparse for patients with advanced cholangiocarcinoma after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements occur in 10-16% of patients with intrahepatic cholangiocarcinoma. Infigratinib is...
7.
Pfister D, Gonzalo Nunez N, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al.
Nature
. 2021 Mar;
592(7854):450-456.
PMID: 33762733
Hepatocellular carcinoma (HCC) can have viral or non-viral causes. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients...
8.
Waidmann O, Pelzer U, Boeck S, Waldschmidt D
Z Gastroenterol
. 2018 Jun;
56(6):578-582.
PMID: 29890560
Pancreatic cancer is one of the most lethal cancer diseases. For years, gemcitabine has been the standard of care and the only therapeutic option in patients with metastatic pancreatic cancer....